ASH: Merck's Keytruda nabs speedy FDA review in non-Hodgkin lymphoma
admin 12th December 2017 Uncategorised 0ATLANTA—Merck’s quest to move Keytruda further into blood cancers hit a snag over the summer, but now, it’s back on track. The FDA has accepted the New Jersey drugmaker’s application for the immuno-oncology star in previously treated primary mediastinal large B-cell lymphoma, a form of non-Hodgkin lymphoma.
More: ASH: Merck's Keytruda nabs speedy FDA review in non-Hodgkin lymphoma
Source: fierce